{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:51:24Z","timestamp":1791298284900,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C47608\/A29957"],"award-info":[{"award-number":["C47608\/A29957"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRIS Cancer Foundation The Institute of Cancer Research"},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["S_4267"],"award-info":[{"award-number":["S_4267"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01632-6","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:59:03Z","timestamp":1791295143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SETD2 is a novel and druggable dependency in IMiD\/CELMoD resistant multiple myeloma models"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-0937","authenticated-orcid":false,"given":"Sarah A.","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco P.","family":"Licciardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Mandelia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakinthi","family":"Chrisochoidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-214X","authenticated-orcid":false,"given":"Yigen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-1657","authenticated-orcid":false,"given":"Fernando J.","family":"Sialana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-1290","authenticated-orcid":false,"given":"Paul A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1632_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1182\/blood-2021-151147","volume":"138","author":"J Totman","year":"2021","unstructured":"Totman J, Brach D, Motwani V, Howe S, Deutschman E, Lampe J, et al. Pharmacologic inhibition of the histone methyltransferase SETD2 with EZM0414 as a novel therapeutic strategy in relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. Blood. 2021;138:1142.","journal-title":"Blood"},{"key":"1632_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00018-022-04352-9","volume":"79","author":"TM Molenaar","year":"2022","unstructured":"Molenaar TM, van Leeuwen F. SETD2: from chromatin modifier to multipronged regulator of the genome and beyond. Cell Mol Life Sci. 2022;79:346.","journal-title":"Cell Mol Life Sci"},{"key":"1632_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.37","volume":"2","author":"A Kalff","year":"2012","unstructured":"Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012;2:e89.","journal-title":"Blood Cancer J"},{"key":"1632_CR4","doi-asserted-by":"publisher","first-page":"3207-","DOI":"10.1182\/blood-2018-99-110803","volume":"132","author":"MJ Thomenius","year":"2018","unstructured":"Thomenius MJ, Totman J, Cosmopoulos K, Brach D, Ci L, Farrow N, et al. Identification of a first-in-class SETD2 inhibitor that shows potent and selective anti-proliferative activity in t(4;14) multiple myeloma: T(4;14) multiple myeloma cells are dependent on both H3K36 di and tri-methylation. Blood. 2018;132:3207-.","journal-title":"Blood"},{"key":"1632_CR5","doi-asserted-by":"crossref","unstructured":"Bird SA, Licciardello MP, Sukhtankar A, Morales S, Sialana FJ, Xu Y, et al. IMiD\/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable. Blood Neoplasia. 2026:100281.","DOI":"10.1016\/j.bneo.2026.100281"},{"key":"1632_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster JM, Boyle I, Vazquez F, Root DE, Boehm JS, Hahn WC, et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021;22:343.","journal-title":"Genome Biol"},{"key":"1632_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","volume":"20","author":"F Cottini","year":"2022","unstructured":"Cottini F, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, et al. Redefining CD56 as a biomarker and therapeutic target in multiple myeloma. Mol Cancer Res. 2022;20:1083\u201395.","journal-title":"Mol Cancer Res"},{"key":"1632_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.18632\/oncotarget.28350","volume":"14","author":"F Cottini","year":"2023","unstructured":"Cottini F, Benson D. To be or not to be: the role of CD56 in multiple myeloma. Oncotarget. 2023;14:47\u20139.","journal-title":"Oncotarget"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01632-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:59:06Z","timestamp":1791295146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01632-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01632-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ICR has a commercial interest in the development of compounds targeting the\u00a0CRL4-CRBN E3-ubiquitin ligase. CP has received honoraria from Celgene\/BMS (manufacturer of IMiDs\/CELMoDs) for advisory boards, educational talks and participation in data monitoring committees. All other authors have no relevant conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"172"}}